SHH and breast cancer: In a phase I clinical trial of the SMO inhibitor sonidegib combined with docetaxel chemotherapy in patients with metastatic triple-negative BC, 25% of patients derived clinical benefit and one patient had a complete response, suggesting that in specific circumstances, SHH signal blockade may enable tumors to respond to chemotherapy [472].